Invex Therapeutics (ASX:IXC) Total Liabilities: A$0.18 Mil (As of Dec. 2025)


What is Invex Therapeutics Total Liabilities?

Invex Therapeutics ASX:IXC -9.09% Total Liabilities is A$0.18 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was A$0.18 Mil.

Invex Therapeutics's quarterly Total Liabilities declined from Dec. 2024 (A$0.48 Mil) to Jun. 2025 (A$0.22 Mil) and declined from Jun. 2025 (A$0.22 Mil) to Dec. 2025 (A$0.18 Mil).

Invex Therapeutics's annual Total Liabilities declined from Jun. 2023 (A$1.57 Mil) to Jun. 2024 (A$0.43 Mil) and declined from Jun. 2024 (A$0.43 Mil) to Jun. 2025 (A$0.22 Mil).

Invex Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Total Liabilities Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial 0.66 1.00 1.57 0.43 0.22

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.43 0.48 0.22 0.18

Invex Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Invex Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.221+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.22

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=5.468-5.247
=0.22

Invex Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.176+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.18

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=4.723-4.547
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$0.18 Mil mean?
Invex Therapeutics (ASX:IXC) has a Total Liabilities of A$0.18 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Total Liabilities too high?
Invex Therapeutics' current Total Liabilities is A$0.18 Mil.
How does Invex Therapeutics' Total Liabilities compare to VRTX and REGN?
Invex Therapeutics' Total Liabilities of A$0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Total Liabilities is A$0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Total Liabilities of A$0.18 Mil. The current Total Liabilities is A$0.18 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Total Liabilities is A$0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.